This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, H. Articles by Livingston, P. O. Search for Related Content PubMed Articles by Zhang, H. Articles by Livingston, P. O.

Antibodies against GD2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases¹

Departments of Medicine [H. Z., S. Z., G. R., P. O. L.] and Pediatrics [N-K. V. C.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

After 10 years of clinical trials in patients with advanced cancer, monoclonal antibodies (mAbs) against cell surface antigens have not lived up to their initial promise. One such cell surface antigen is the ganglioside GD2. GD2 is richly expressed at the cell surfaces of human neuroblastomas, sarcomas, and melanomas. We have described a murine lymphoma (EL4) that is syngeneic in C57BL/6 mice and expresses GD2, a mAb against GD2 (mAb 3F8), and we have prepared a conjugate vaccine (GD2-keyhole limpet hemocyanin plus immunological adjuvant QS-21) that consistently induces antibodies against GD2. We demonstrate here, for the first time in a syngeneic murine model, that passively administered and vaccine-induced antiganglioside antibodies prevent outgrowth of micrometastases, and we use this model to establish some of the parameters of this protection. The level of protection was proportional to antibody titer. Treatment regimens resulting in the highest titer antibodies induced the most protection, and protection was demonstrated even when immunization was initiated after tumor challenge. Treatment with 3F8 1, 2, or 4 days after i.v. tumor challenge was highly protective, but waiting until 7 or 10 days after challenge resulted in minimal protection. The results were similar whether number of liver metastases or survival was used as the end point. These results suggest that unmodified mAbs or antibody-inducing vaccines against GD2 (and possibly other cancer cell surface antigens) should be used exclusively in the adjuvant setting, where circulating tumor cells and micrometastases are the primary targets.

¹ This work was supported by NIH Grants PO1 CA 33049 (to P. O. L. and G. R.) and RO1 CA 61017 (N-K. V. C.). P. O. L. is a paid consultant to and has share options in Progenics Pharmaceuticals, Inc., who has licensed the GD2-KLH vaccine from Memorial Sloan-Kettering Cancer Center. In exchange for the rights conveyed under the licensing agreement, Memorial Sloan-Kettering Cancer Center received shares in Progenics Pharmaceuticals, Inc., in lieu of a licensing fee.

² To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Fax: (212) 794-4352.

Received 1/22/98. Accepted 4/28/98.

This article has been cited by other articles:

				S. M. Knoepp, M. S. Chahal, Y. Xie, Z. Zhang, D. J. Brauner, M. A. Hallman, S. A. Robinson, S. Han, M. Imai, S. Tomlinson, et al. Effects of Active and Inactive Phospholipase D2 on Signal Transduction, Adhesion, Migration, Invasion, and Metastasis in EL4 Lymphoma Cells Mol. Pharmacol., September 1, 2008; 74(3): 574 - 584. [Abstract] [Full Text] [PDF]

				N. Alvarez-Rueda, S. Leprieur, B. Clemenceau, S. Supiot, V. Sebille-Rivain, A. Faivre-Chauvet, F. Davodeau, F. Paris, J. Barbet, J. Aubry, et al. Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen Clin. Cancer Res., September 15, 2007; 13(18): 5613s - 5620s. [Abstract] [Full Text] [PDF]

				P. J. Sabbatini, G. Ragupathi, C. Hood, C. A. Aghajanian, M. Juretzka, A. Iasonos, M. L. Hensley, M. K. Spassova, O. Ouerfelli, D. R. Spriggs, et al. Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4170 - 4177. [Abstract] [Full Text] [PDF]

				G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al. TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction J. Immunol., May 15, 2007; 178(10): 6642 - 6652. [Abstract] [Full Text] [PDF]

				M. J. Morris, N. Pandit-Taskar, C. R. Divgi, S. Bender, J. A. O'Donoghue, A. Nacca, P. Smith-Jones, L. Schwartz, S. Slovin, R. Finn, et al. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2707 - 2713. [Abstract] [Full Text] [PDF]

				M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer Cancer Res., November 15, 2005; 65(22): 10562 - 10568. [Abstract] [Full Text] [PDF]

				M. J. Morris, C. R. Divgi, N. Pandit-Taskar, M. Batraki, N. Warren, A. Nacca, P. Smith-Jones, L. Schwartz, W. K. Kelly, S. Slovin, et al. Pilot Trial of Unlabeled and Indium-111-Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7454 - 7461. [Abstract] [Full Text] [PDF]

				M. W. Retter, J. C. Johnson, D. W. Peckham, J. E. Bannink, C. S. Bangur, K. Dresser, F. Cai, T. M. Foy, N. A. Fanger, G. R. Fanger, et al. Characterization of a Proapoptotic Antiganglioside GM2 Monoclonal Antibody and Evaluation of Its Therapeutic Effect on Melanoma and Small Cell Lung Carcinoma Xenografts Cancer Res., July 15, 2005; 65(14): 6425 - 6434. [Abstract] [Full Text] [PDF]

				B. Monzavi-Karbassi, C. Artaud, F. Jousheghany, L. Hennings, J. Carcel-Trullols, S. Shaaf, S. Korourian, and T. Kieber-Emmons Reduction of Spontaneous Metastases through Induction of Carbohydrate Cross-Reactive Apoptotic Antibodies J. Immunol., June 1, 2005; 174(11): 7057 - 7065. [Abstract] [Full Text] [PDF]

				G. Ragupathi, N. X. Liu, C. Musselli, S. Powell, K. Lloyd, and P. O. Livingston Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity J. Immunol., May 1, 2005; 174(9): 5706 - 5712. [Abstract] [Full Text] [PDF]

				K. A. Gelderman, P. J. K. Kuppen, N. Okada, G. J. Fleuren, and A. Gorter Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model Cancer Res., June 15, 2004; 64(12): 4366 - 4372. [Abstract] [Full Text] [PDF]

				W. Zou, S. Borrelli, M. Gilbert, T. Liu, R. A. Pon, and H. J. Jennings Bioengineering of Surface GD3 Ganglioside for Immunotargeting Human Melanoma Cells J. Biol. Chem., June 11, 2004; 279(24): 25390 - 25399. [Abstract] [Full Text] [PDF]

				S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785. [Abstract] [Full Text] [PDF]

				G. Ragupathi, P. O. Livingston, C. Hood, J. Gathuru, S. E. Krown, P. B. Chapman, J. D. Wolchok, L. J. Williams, R. C. Oldfield, and W.-J. Hwu Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21 Clin. Cancer Res., November 1, 2003; 9(14): 5214 - 5220. [Abstract] [Full Text] [PDF]

				G. Ragupathi, D. M. Coltart, L. J. Williams, F. Koide, E. Kagan, J. Allen, C. Harris, P. W. Glunz, P. O. Livingston, and S. J. Danishefsky On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines PNAS, October 15, 2002; 99(21): 13699 - 13704. [Abstract] [Full Text] [PDF]

				S. Yoshida, S. Fukumoto, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa Ganglioside GD2 in Small Cell Lung Cancer Cell Lines: Enhancement of Cell Proliferation and Mediation of Apoptosis Cancer Res., May 1, 2001; 61(10): 4244 - 4252. [Abstract] [Full Text]

				Z.-G. Wang, L. J. Williams, X.-F. Zhang, A. Zatorski, V. Kudryashov, G. Ragupathi, M. Spassova, W. Bornmann, S. F. Slovin, H. I. Scher, et al. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: Isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens PNAS, March 14, 2000; 97(6): 2719 - 2724. [Abstract] [Full Text] [PDF]

				R. Chammas, J. L. Sonnenburg, N. E. Watson, T. Tai, M. G. Farquhar, N. M. Varki, and A. Varki De-N-acetyl-gangliosides in Humans: Unusual Subcellular Distribution of a Novel Tumor Antigen Cancer Res., March 1, 1999; 59(6): 1337 - 1346. [Abstract] [Full Text] [PDF]